@article{MTMT:34775499,
	title = {Frequency of office blood pressure measurements and the seasonal variability of blood pressure: results of the Hungarian Hypertension Registry},
	url = {https://m2.mtmt.hu/api/publication/34775499},
	author = {Nemcsik, János and Takács, Johanna and Pásztor, Dorottya Tímea and Farsang, Csaba and Simon, Attila and Páll, Dénes and Torzsa, Péter and Dolgos, Szilveszter and Koller, Ákos and Habony, Norbert and Járai, Zoltán},
	doi = {10.1080/08037051.2024.2337170},
	journal-iso = {BLOOD PRESSURE},
	journal = {BLOOD PRESSURE},
	volume = {33},
	unique-id = {34775499},
	issn = {0803-7051},
	year = {2024},
	eissn = {1651-1999},
	orcid-numbers = {Nemcsik, János/0000-0002-3573-0287; Takács, Johanna/0000-0002-8709-8826; Pásztor, Dorottya Tímea/0009-0001-8399-1019; Torzsa, Péter/0000-0002-8148-4961; Koller, Ákos/0000-0003-3256-8701}
}

@article{MTMT:34750605,
	title = {A renin-angiotenzin rendszer és az angiotenzinreceptorgátlók legfontosabb hatásai : Fókuszban a valzartán},
	url = {https://m2.mtmt.hu/api/publication/34750605},
	author = {Farsang, Csaba},
	doi = {10.33668/hn.28.005},
	journal-iso = {HYPERTONIA NEPHROLOGIA},
	journal = {HYPERTONIA ÉS NEPHROLOGIA},
	volume = {28},
	unique-id = {34750605},
	issn = {1418-477X},
	abstract = {Az AT1-receptor-antagonisták (ARB) hatására az arteriolákon vasodilatatio következik be, ezért a teljes perifériás érellenállás (TPR) csökken, csökken az aldoszteronszekréció is és a Na-reabszorpció és a vízreabszorpció a vesetubulusokban.},
	year = {2024},
	eissn = {2498-6259},
	pages = {43-46}
}

@article{MTMT:34147505,
	title = {Melyek az Európai Hypertonia Társaság 2023. évi irányelvének legfontosabb újdonságai?},
	url = {https://m2.mtmt.hu/api/publication/34147505},
	author = {Járai, Zoltán and Farsang, Csaba and Nemcsik, János and Páll, Dénes},
	journal-iso = {HYPERTONIA NEPHROLOGIA},
	journal = {HYPERTONIA ÉS NEPHROLOGIA},
	volume = {27},
	unique-id = {34147505},
	issn = {1418-477X},
	year = {2023},
	eissn = {2498-6259},
	pages = {180-184},
	orcid-numbers = {Nemcsik, János/0000-0002-3573-0287}
}

@article{MTMT:33198360,
	title = {Gyógyszeres kezelési stratégiák, hypertoniás sürgôsségi állapotok},
	url = {https://m2.mtmt.hu/api/publication/33198360},
	author = {Farsang, Csaba},
	doi = {10.33616/lam.32.033},
	journal-iso = {LEGE ART MED},
	journal = {LEGE ARTIS MEDICINAE},
	volume = {32},
	unique-id = {33198360},
	issn = {0866-4811},
	abstract = {A közleményben összefoglalom a hypertoniás betegek gyógyszeres kezelésére, és külön fejezetrészben a hypertoniás sürgôsségi állapotokra vonatkozó jelenleg érvényes gyógyszeres kezelési irányelveket.},
	keywords = {Gyógyszeres kezelés; hypertonia},
	year = {2022},
	eissn = {2063-4161},
	pages = {427-433}
}

@article{MTMT:32708145,
	title = {Orvosi levelek a Covid-19-ről. II. rész},
	url = {https://m2.mtmt.hu/api/publication/32708145},
	author = {Farsang, Csaba},
	journal-iso = {HYPERTONIA NEPHROLOGIA},
	journal = {HYPERTONIA ÉS NEPHROLOGIA},
	volume = {25},
	unique-id = {32708145},
	issn = {1418-477X},
	abstract = {2020 márciusában hazánkat is elérte a koronavírus-járvány, amelynek sokirányú hatása volt és van az egész társadalomra, az orvosi közösségekre és legnagyobb mértékben a betegekre. A második levélben az orvosi segítség keresése, a betegek tünetei, a stressz és a fizikai aktivitás szerepével és jelentőségével foglalkozom.},
	year = {2021},
	eissn = {2498-6259},
	pages = {79-80}
}

@article{MTMT:32099838,
	title = {Hypertonia, COPD és Covid-19. Fókuszban az antihipertenzív terápia},
	url = {https://m2.mtmt.hu/api/publication/32099838},
	author = {Farsang, Csaba},
	doi = {10.33616/LAM.31.013},
	journal-iso = {LEGE ART MED},
	journal = {LEGE ARTIS MEDICINAE},
	volume = {31},
	unique-id = {32099838},
	issn = {0866-4811},
	abstract = {Chronic obstructive pulmonary disease is a very common comorbidity of hypertension and it is often unrecognised by physicians. The factors involved in the pathomechanism of both diseases should be realised when choosing treatment. Among factors, hypoxia, increased tone of sympathetic nervous system and activation of reninangiotensin- aldosterone system should primarily be considered. Vascular wall damage and endothelial dysfunction has an important role in both conditions. The goals of treatment are elimination of risk factors, optimizing the blood pressure, the consequential prevention of cardio-cerebrovascular, renal and pulmonary damage; finally prolonging the patients' life and improving their quality of life as well. Both hypertension and COPD significantly worsen the condition of COVID-19 patients since they increase the severity of the disease and the rate of in-patients' and their mortality. In the treatment of hypertension among COPD and COVID-19 patients there must be emphasized the medication inhibiting of renin-angiotensin-aldosterone system, such as angiotensin-converting en - zyme inhibitors or angiotensin-II AT1 re - cep tor antagonists. Special attention concerned the beneficial effect of mineralocorticoid receptor antagonist spironolactone. Other antihypertensive drugs (calcium channel blockers, thiazide-like diu retics, high selectivity β1 receptor antagonists) may supplement the treatment if necessary. Long-acting β2 receptor agonists, muscarinic receptor antagonists and inhalation corticosteroids may be administered in double or triple combination also in hypertension and COPD as well. It is important to note, that statin therapy and also vitamin D3 improve the condition of COVID-19 patients. © 2021 Literatura Medica Publishing House. All rights reserved.},
	keywords = {PATHOPHYSIOLOGY; Therapy; HYPERTENSION; COPD; COVID-19},
	year = {2021},
	eissn = {2063-4161},
	pages = {193-199}
}

@article{MTMT:31945045,
	title = {Orvosi levelek a Covid-19-ről. I. rész},
	url = {https://m2.mtmt.hu/api/publication/31945045},
	author = {Farsang, Csaba},
	journal-iso = {HYPERTONIA NEPHROLOGIA},
	journal = {HYPERTONIA ÉS NEPHROLOGIA},
	volume = {25},
	unique-id = {31945045},
	issn = {1418-477X},
	abstract = {2020 márciusában hazánkat is elérte a koronavírus-járvány, amelynek sokirányú hatása volt és van az egész társadalomra, az orvosi közösségekre és legnagyobb mértékben a betegekre. Az alábbiakban és a következő levélben megpróbálom összefoglalni az általam kiválasztott és legfontosabbnak tartott, a fentieket érintő témákat. Nem fogok írni a tünetekről és a terápiáról, célom a járvány közösségi hatásainak bemutatása.},
	keywords = {társadalomtudomány; COVID-19; Covid-19-járvány; Covid-19-betegség; COVID-19 infekciókontroll; SARS-CoV-2- (Covid-19-vírus-) fertôzés},
	year = {2021},
	eissn = {2498-6259},
	pages = {31-32}
}

@article{MTMT:31930771,
	title = {Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies},
	url = {https://m2.mtmt.hu/api/publication/31930771},
	author = {Farsang, Csaba and Dézsi, Csaba András and Brzozowska-Villatte, Romualda and De, Champvallins Martine and Glezer, Maria and Karpov, Yuri},
	doi = {10.1007/s12325-021-01619-8},
	journal-iso = {ADV THER},
	journal = {ADVANCES IN THERAPY},
	volume = {38},
	unique-id = {31930771},
	issn = {0741-238X},
	abstract = {Introduction To assess real-life effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in patients with hypertension (HT) and type 2 diabetes mellitus (T2DM), obesity and/or metabolic syndrome (MetS). Methods This post hoc analysis pooled raw data from four large observational studies (FORTISSIMO, FORSAGE, ACES, PICASSO). Patients, most with uncontrolled blood pressure (BP) on previous treatments were switched to Per/Ind (10 mg/2.5 mg) SPC at study entry. Office systolic and diastolic blood pressures (SBP and DBP) were measured at baseline, 1 month and 3 months. Results In the overall pooled population (N = 16,763), mean age was 61 +/- 12 years, HT duration 11 +/- 8 years, and baseline SBP/DBP 162/94 mmHg. T2DM, obesity and MetS were present in 21%, 49% and 27% of patients, respectively. Subgroups had similar mean age and HT duration to the overall population; patients with T2DM were slightly older (64 +/- 10 years) with a longer HT duration (13 +/- 8 years). Mean BP was approximately 160/95 mmHg in each subgroup. At 1 month, mean SBP decreased by approximately 20 mmHg in the overall population, and by a further 10 mmHg at 3 months. Similar results were observed in the three subgroups, with mean changes from baseline at 3 months of - 28 +/- 15/- 13 +/- 10 in T2DM; - 30 +/- 15/- 14 +/- 10 in obesity; and - 31 +/- 15/- 15 +/- 9 mmHg in MetS. BP decreases were greatest in patients with grade II or grade III HT. BP control rates (< 140/90 mmHg or 140/85 mmHg for T2DM) at 3 months were 59% in T2DM, 67% in obese, and 66% in MetS. No specific safety concerns were raised, particularly concerning ionic (Na, K) or metabolic profiles. Conclusions Switching to Per/Ind SPC led to rapid and effective BP decreases in patients with T2DM, obesity, or MetS. BP control was achieved in 6-7 out of 10 previously treated but uncontrolled patients. Treatment was well tolerated. The results confirm the beneficial effects of a Per/Ind SPC for difficult-to-control patient populations.},
	keywords = {HYPERTENSION; OBESITY; metabolic syndrome; perindopril; indapamide; Blood pressure control; Medicine, Research & Experimental; Single-pill combination; Type},
	year = {2021},
	eissn = {1865-8652},
	pages = {1776-1790}
}

@article{MTMT:31671935,
	title = {Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO Observational Studies},
	url = {https://m2.mtmt.hu/api/publication/31671935},
	author = {Dézsi, Csaba András and Glezer, Maria and Karpov, Yuri and Brzozowska-Villatte, Romualda and Farsang, Csaba},
	doi = {10.1007/s12325-020-01527-3},
	journal-iso = {ADV THER},
	journal = {ADVANCES IN THERAPY},
	volume = {38},
	unique-id = {31671935},
	issn = {0741-238X},
	abstract = {Introduction Our objective was to determine the effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in a broad range of patient profiles, including subgroups with varying hypertension severity, age and cardiovascular risk profiles. Methods Patient data from four large prospective observational studies (FORTISSIMO, FORSAGE, PICASSO, ACES) were pooled. In each study, patients already treated for hypertension were switched to Per/Ind 10/2.5 mg SPC and systolic and diastolic blood pressure (SBP/DBP) measured at the 1-month (M1) and 3-month (M3) visits. Study endpoints included change in SBP and DBP from baseline to M1 and M3 and the percentage of patients achieving BP control (SBP/DBP < 140/90 mmHg for patients without diabetes or < 140/85 mmHg for patients with diabetes). Results A total of 16,763 patients were enrolled and received Per/Ind (94% received the full dose of 10/2.5). Mean patient age was 61.4 years (36% were >= 65 years old), 57% were women, and 16% had isolated systolic hypertension (ISH). Mean baseline office SBP/DBP was 162/94 mmHg, and mean duration of hypertension was 11 years. Cardiovascular risk factors and comorbid conditions were common in this population. Significant mean reductions in SBP (- 23 mmHg) and DBP (- 11 mmHg) were observed at M1 compared with baseline (P < 0.001), which were maintained at M3 (- 30 mmHg and - 14 mmHg, respectively). At M3, BP control was achieved by 70% of patients (78% for ISH). In patients with SBP >= 180 mmHg at baseline (grade III hypertension), the mean SBP/DBP decrease was - 51/- 20 mmHg and 53% achieved BP control. Per/Ind was well tolerated with an overall rate of adverse events of 1.3%, most frequently cough and dizziness at rates of 0.3% and 0.2%, respectively. Conclusion In this hypertensive population including difficult-to-control patient subgroups, switching to Per/Ind 10/2.5 mg SPC led to rapid and important reductions in BP. BP control was achieved in 70% of patients overall in an everyday practice context.},
	keywords = {BLOOD-PRESSURE; TYPE-2 DIABETES-MELLITUS; HYPERTENSION; EFFICACY; Diabetes; perindopril; Regression; CARDIOVASCULAR EVENTS; Cardiovascular risk; antihypertensive therapy; indapamide; indapamide; Blood pressure control; FIXED-DOSE COMBINATION; Medicine, Research & Experimental; Single-pill combination; angiotensin-converting enzyme inhibitor; Thiazide-like diuretics},
	year = {2021},
	eissn = {1865-8652},
	pages = {479-494},
	orcid-numbers = {Dézsi, Csaba András/0000-0002-7203-0423}
}

@article{MTMT:33557841,
	title = {A Magyar Hypertónia Társaság és a Magyar Reumatológusok Egyesületének konszenzus dokumentuma: A hyperurikaemiás és a köszvényes betegek ellátásáról.},
	url = {https://m2.mtmt.hu/api/publication/33557841},
	author = {Járai, Zoltán and Alföldi, S and Mátyus, János and Ábrahám, György and Balog, A and Csiky, Botond and Farsang, Csaba and Kumánovics, Gábor and Pálinkás, Márton and Páll, Dénes and Reusz, György and Tislér, András and Szekanecz, Zoltán},
	journal-iso = {HYPERTONIA NEPHROLOGIA},
	journal = {HYPERTONIA ÉS NEPHROLOGIA},
	volume = {24},
	unique-id = {33557841},
	issn = {1418-477X},
	year = {2020},
	eissn = {2498-6259},
	pages = {S1-S20},
	orcid-numbers = {Ábrahám, György/0000-0002-2272-2317; Reusz, György/0000-0003-0396-043X; Tislér, András/0000-0002-1265-1869}
}